Jarushka Naidoo: A privilege to hear Nobel Prize Winner Jim Allison

Jarushka Naidoo posted on X:

“A privilege to hear Nobel Prize Winner Jim Allison take his seminal discovery of CTLA4 forward.

Some thoughts:

• move beyond PD1, CTLA4, LAG3
• tetrad ICI biomarkers
• perioperative trials.”

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.

Jim Allison is Regental Professor and Chair of Immunology at MD Anderson Cancer Center, where he also directs the Parker Institute for Cancer Research and the James P. Allison Institute. Awarded the 2018 Nobel Prize in Physiology or Medicine with Dr. Tasuku Honjo for their work on immune checkpoint inhibitors, his research focuses on enhancing these therapies and discovering new targets to boost immune responses against cancer.